In a recent study published in Annals of Internal Medicine, sodium glucose cotransporter-2 (SGLT2) inhibitors were found to have a reduced risk for gout as compared to glucagon like peptide 1 (GLP-1) agonist. In this study patient taking SGLT2 inhibitor had 36% reduced risk of developing gout. The study design, population-based cohort study, is not the most robust study design as well as gout risk factors were not accessed in the study. While this is promising, more studies are needed.
Please share your thoughts and subscribe to receive my blogs.
#gout #reduction #SGLT-2 inhibitors
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.